From the Department of Health The Department of Health (DOH) today advised persons with epilepsy (PWEs) to take their medications regularly and have a regular check up to prevent seizures and lead a normal life as the country observes National Epilepsy Awareness Week onSeptember 1-7, 2013. This years theme, Epilepsy ABC:AwarenessBegins inCommunities (Kaya Natin To!),underscores the need to promote epilepsy awareness and inclusion of PWEs in various levels of engagement like health, education, welfare, and development through community-centered activities. Secretary of Health Enrique T. Ona revealed that epilepsy is present in around 1% of the global population and may be higher in developing countries. In study conducted bythe National Nutrition and Health Survey that was published in the journal of Neurology in 2003, disclosed that there are 230 persons with epilepsy per 100,000 populations in the Philippines. Epilepsy is the second most common consultation with a neurologist, second to stroke. Ona added that epilepsy is more common among the very young and the very old, although it can strike individuals of any age. The mortality rate among people with epilepsy is two to three times higher than the general population and the risk of sudden death is 24 times greater. … Continue reading →

DEERFIELD, Ill.--(BUSINESS WIRE)-- Lundbecks epilepsy research efforts are featured in a new report on neurological disorders from the Pharmaceutical Research and Manufacturers of America (PhRMA). The report is accompanied by an educational video about the science of epilepsy, including the role of neuroinflammation and how a better understanding of the neuroinflammatory processes may yield new seizure therapies. The video can be viewed here. The video features three scientists from Lundbecks US research organization. Lundbeck researchers in the U.S. focus entirely on brain disorders, exploring the role of neuroinflammation in conditions including Alzheimers disease, depression, Parkinsons disease, schizophrenia, epilepsy and others. Almost every neurological disease that has been studied has been shown to have some component of neuroinflammation, said Stevin Zorn, PhD, executive vice president of Lundbeck Research USA. By studying neuroinflammation biologies, were hoping to identify new ways to treat complicated neurological disorders like epilepsy and related seizure disorders. While this research has a ways to go before reaching the bedside, it has the potential to play an important role in the future treatment of epilepsy. Partnering to Make a Difference in Epilepsy In addition to its own R&D efforts, Lundbeck supports the scientific and professional epilepsy community to accelerate … Continue reading →

Autism: What Do I Do? Autism: What Do I Do? from Autism Live. Like this? Watch the latest episode of Autism Live on Blip! http://blip.tv/autismlive/watch Like Autism Live on Faceb... By: AutismLive … Continue reading →

"Local Family Using Breakthrough Autism Treatment" Mobile, AL. NBC News Story http://www.integratedlistening.com/wp-content/ils-files//2010/04/NBC-Local-15-Jan.-1-2013.pdf. By: IntegratedListening … Continue reading →

Scientists have grown the first mini human brains in a laboratory and say their success could lead to new levels of understanding about the way brains develop and what goes wrong in disorders like schizophrenia and autism. Researchers based in Austria started with human stem cells and created a culture in the lab that allowed them to grow into so-called cerebral organoids - or mini brains - that consisted of several distinct brain regions. It is the first time that scientists have managed to replicate the development of brain tissue in three dimensions. Using the organoids, the scientists were then able to produce a biological model of how a rare brain condition called microcephaly develops - suggesting the same technique could in future be used to model disorders like autism or schizophrenia that affect millions of people around the world. This study offers the promise of a major new tool for understanding the causes of major developmental disorders of the brain ... as well as testing possible treatments, said Paul Matthews, a professor of clinical neuroscience at Imperial College London, who was not involved in the research but was impressed with its results. Zameel Cader, a consultant neurologist at Britains … Continue reading →

NEW HAVEN, Conn. Heres a frightening statistic: One in every fifty school children in the US will be diagnosed with autism. Unfortunately, it can take doctors years to identify the disorder, delaying much needed treatment, but a new research may help doctors predict a childs risk of developing autism at birth! Skiing alongside 12-year-old Jaya Dominici, you wouldnt know that shes severely autistic, unless, you try to talk to her. Maria suspected her daughter was autistic at 18-months, but she wasnt diagnosed until three. It was really like a baseball bat right to the head, because you know its going to be forever," Maria Dominici, Jaya's Mother, told Ivanhoe. Early detection is critical, because the brain is completely unformed at birth. We can change behaviors very early, Doctor Harvey J. Kliman, MD, PhD, a Research Scientist in the Department of Obstetrics and Gynecology at the Yale University School of Medicine, told Ivanhoe. A new study examining the placenta, the organ that provides nutrients to the baby from the mother, may help doctors diagnose autism shortly after birth. Researchers analyzed placentas from 217 births and found that in families at high genetic risk for having an autistic child, there were more … Continue reading →

Philadelphia, PA - Olfactory Biosciences Corp. (OLFC) the makers of NOXO Autism Aid(TM) announce today the success of their innovative Autism balm. NOXO's solution provides unprecedented hope for families isolated by behavioral issues related to sensitivities and overstimulation in children with Autism. NOXO stops the frequency of behavioral issues that trouble children with sensitivities by stopping irritant odors and inducing a calming effect. Providing relief to the overstimulated child and allowing families to enjoy public settings with fewer worries. NOXO Autism Aid(TM) is similar to a lip balm but is applied just below the nostrils on the upper lip. Allowing the natural formula to be inhaled and take effect. NOXOs solution is safe, easy to apply and non-invasive. It works on your bodys natural processes and responses. It is the first product to address behavioral issues triggered by sensitivities. A parent seeking help, Allan Chang, shares his experience with NOXO Autism Aid(TM), "Just like any father, I tried many types of treatment . . . , but to no avail. What attracted me with the NOXO Autism balm is that it is a topical application. I can easily apply it with no power struggle with him. It's been 10 days … Continue reading →

Newswise Scientists at the Seaver Autism Center at the Icahn School of Medicine at Mount Sinai have received a grant from the National Institutes of Health (NIH) to study Insulin-Like Growth Factor-1 (IGF-1), a promising treatment for a subtype of autism called Phelan McDermid Syndrome (PMS). The grant will allow researchers to expand upon an ongoing study assessing the clinical benefit of IGF-1 in children with this severe type of autism. IGF-1 is a commercially-available compound for growth deficiency that is known to promote nerve cell survival as well as synaptic maturation and plasticity. The primary aim of the study is to target core features of PMS, including social withdrawal and language impairment, which will be measured using both behavioral and objective assessments. So far, nine patients have participated in a pilot study to assess safety and feasibility of IGF-1. The Seaver Autism Center team hopes to enroll 18 more participants with support from the NIH grant, in order to establish statistically significant clinical benefit of IGF-1. The NIH will provide more than $750,000 over three years to study IGF-1. With the grant, Alex Kolevzon, MD, Clinical Director the Seaver Autism Center, will continue to enroll children ages 5 to … Continue reading →

LOS ANGELES--(BUSINESS WIRE)-- Targeted Medical Pharma, Inc. (TRGM) today announced that the company will begin a clinical trial on a new medical food indicated for the dietary management of Autism and Autism Spectrum Disorders. This open label trial will measure the changes in blood concentrations of specific amino acids, behavior, mood, and sleep patterns over a thirty day period following a twice daily oral administration of the companys new medical food. Subjects will be screened for enrollment based on medical history and diagnosis of Autism or any Autism Spectrum Disorders. Autism and Autistic Spectrum have long been recognized to be associated with reduced absorption of amino acids and a decrease in several brain neurotransmitters. With our targeted cellular technology platform, we believe that this product may be able to increase the concentration of the necessary amino acid precursors and brain neurotransmitters that are diminished in patients with autism, said David Silver, M.D., President and Chief Operating Officer at Targeted Medical Pharma, Inc. Our company has established that treating an underlying nutritional deficiency of a disease with a medical food can greatly reduce symptoms and improve clinical outcomes. Autism and Autism Spectrum Disorders affect one percent of the population of children … Continue reading →